secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q1 net loss $29.3M; DURAVYU Phase 2 NPDR trial misses primary endpoint; cash runway to 2026
--------------------------------------------------------------------------------

- Q1 net loss $29.3M ($0.55/shr) vs $21.2M ($0.56/shr) in Q1 2023; revenue $11.7M (+52% YoY) from YUTIQ deferred revenue.
- Product revenue fell to $0.7M from $7.4M due to out-license of YUTIQ franchise in May 2023.
- Phase 2 PAVIA trial of DURAVYU in NPDR missed primary endpoint; biologic effect observed; 12-month data expected Q3 2024.
- Phase 3 LUGANO trial for DURAVYU in wet AMD on track for 2H 2024; Phase 2 VERONA DME data in Q1 2025.
- Cash and investments $299.3M; funds operations through DURAVYU Phase 3 topline data in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024055055/0000950170-24-055055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024055055/eypt-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer